Skip to main content
FDA Alerts

FDA Application Seeks Expanded Lumateperone Approval for Bipolar I Mania

Edited by 

Key Clinical Summary

  • Johnson & Johnson submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking approval of lumateperone (CAPLYTA) for manic or mixed episodes associated with bipolar I disorder in adults.
  • Two phase 3 randomized, placebo-controlled trials demonstrated significant reductions in manic symptoms and overall illness severity with once-daily lumateperone 42 mg, with improvements in manic symptoms observed as early as day 3.
  • Both trials met their primary and key secondary endpoints, according to the manufacturer. 

Johnson & Johnson has submitted an sNDA to the FDA seeking approval of lumateperone (CAPLYTA) for manic or mixed episodes associated with bipolar I disorder in adults, the company announced November 19, 2026. The application is supported by 2 phase 3 trials in which lumateperone significantly reduced manic symptoms compared with placebo, with improvements observed as early as day 3.

Phase 3 Clinical Trial Findings

The submission is supported by findings from Study 451 and Study 452, two randomized, double-blind, placebo-controlled phase 3 trials evaluating lumateperone in adults experiencing manic episodes, with or without mixed features, associated with bipolar I disorder.

Participants received once-daily lumateperone 42 mg or placebo for 3 weeks in both studies. Researchers evaluated change from baseline in Young Mania Rating Scale (YMRS) total score at week 3 as the primary endpoint, while the key secondary endpoint was change in Clinical Global Impression–Severity (CGI-S) score at week 3.

According to the company, both trials met their primary and key secondary endpoints, demonstrating statistically significant improvements in manic symptoms and overall illness severity compared with placebo.

Reductions in manic symptoms were observed as early as day 3 and were sustained through week 3.

The manufacturer also reported that lumateperone was generally well tolerated. Rates of discontinuation were low, with a safety profile consistent with that of previous trials.

Clinical Implications

Lumateperone is currently FDA-approved for schizophrenia, depressive episodes associated with bipolar I or II disorder as monotherapy or adjunctive therapy with lithium or valproate, and major depressive disorder as adjunctive therapy with antidepressants.

The proposed indication would expand its use to manic or mixed episodes in adults with bipolar I disorder, a condition characterized by episodes of elevated or irritable mood and increased energy or activity. However, FDA approval remains pending, and the reported phase 3 findings do not establish authorization for this use.

Expert Commentary

“For people experiencing acute mania, rapid symptom improvement and tolerability are both critical treatment considerations,” said John C. Reed, MD, PhD, executive vice president of Innovative Medicine Research and Development at Johnson & Johnson.

Reed said the phase 3 findings supported the company's decision to seek an expanded indication for lumateperone.

If approved, manic or mixed episodes associated with bipolar I disorder would become the drug's fifth approved use in adults.

Reference
Johnson & Johnson seeks US FDA approval for CAPLYTA in bipolar mania, marking fifth potential indication. News release. Johnson & Johnson; November 19, 2026. Accessed November 19, 2026.